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Periodontitis is an inflammatory disease caused by pathogenic microorganisms and characterized by the destruction of the
periodontium. Obese individuals have an increased risk of periodontitis, and elevated circulating levels of adipokines, such as
nicotinamide phosphoribosyltransferase (NAMPT), may be a pathomechanistic link between both diseases. The aim of this in
vitro study was to examine the regulation of periodontal ligament (PDL) cells by NAMPT and its production under inflammatory
and infectious conditions. NAMPT caused a significant upregulation of 9 genes and downregulation of 3 genes, as analyzed by
microarray analysis. Eight of these genes could be confirmed by real-time PCR: NAMPT induced a significant upregulation of
EGR1,MMP-1, SYT7, ITPKA, CCL2, NTM, IGF2BP3, andNRP1. NAMPT also increased significantly theMMP-1 andCCL2 protein
synthesis. NAMPT was significantly induced by interleukin-1𝛽 and the periodontal microorganism P. gingivalis. NAMPT may
contribute to periodontitis through upregulation of MMP-1 and CCL2 in PDL cells. Increased NAMPT levels, as found in obesity,
may therefore represent a mechanism whereby obesity could confer an increased risk of periodontitis. Furthermore, microbial and
inflammatory signals may enhance the NAMPT synthesis in PDL cells and thereby contribute to the increased gingival and serum
levels of this adipokine, as found in periodontitis.
1. Introduction
Periodontitis is a chronic inflammatory disease, which is
characterized by the destruction of the tooth-supporting
tissues, such as the periodontal ligament (PDL), and caused
by pathogenic microorganisms, such as Porphyromonas
gingivalis, Tannerella forsythia, Treponema denticola, and
Aggregatibacter actinomycetemcomitans. These periodon-
topathogens can trigger local production of proinflamma-
tory mediators, such as interleukin-1𝛽 (IL-1𝛽), cyclooxy-
genase 2 (COX2), as well as chemokine, cc motif, ligand
2 (CCL2), and matrix-degrading proteases, such as matrixso
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metalloproteinase-1 (MMP-1), by infiltrating and resident
cells of the periodontium. As a consequence of the exag-
gerated immunoinflammatory and proteolytic processes, the
periodontal tissues are subjected to degradation and resorp-
tion, which can finally result in tooth loss [1, 2]. Data from the
NationalHealth andNutritionExamination Survey III, which
analyzed the health andnutritional status in theUnited States,
demonstrate that approximately half of the US population
aged≥30 years is afflictedwith periodontitis [3]. Periodontitis
is also associated with systemic diseases and conditions, such
as cardiovascular diseases, diabetes mellitus, and obesity,
and has a negative influence on a wide range of physical,
psychological, and social aspects of quality of life [4–6].
The exact mechanisms underlying the association
between periodontitis and obesity are as yet unknown.
However, it has been suggested that increased serum levels
of adipokines derived from adipose tissue could make obese
individuals more susceptible to periodontitis. The adipose
tissue is not only an energy storage tissue but also acts as
an endocrine organ, from which adipokines, such as nicoti-
namide phosphoribosyltransferase (NAMPT, also known as
visfatin or pre-B-cell colony-enhancing factor 1), are secreted.
Adipokines not only regulate insulin sensitivity and energy
expenditure but also inflammatory and healing processes [7].
NAMPT is mainly produced by macrophages and adipocytes
in the adipose tissue and induces production of inflammatory
mediators and nuclear factor-kappaB (NF𝜅B) activation [8].
High serum levels of NAMPT are found in obesity, metabolic
syndrome, type 2 diabetes, atherosclerosis, and other diseases
[9–11]. Therefore, increased serum levels of NAMPT could
be at least onemechanism, whereby these diseases contribute
to periodontitis. Recently, it has been demonstrated that
NAMPT is also present in high levels in gingival crevicular
fluid (GCF), gingival tissues, and serum from periodontally
diseased patients, indicating that NAMPT might also be
produced locally in the periodontium and play a role in
the etiopathogenesis of periodontitis [12, 13]. However,
whether NAMPT regulates the gene expression and protein
synthesis of periodontal cells has yet to be elucidated.
Furthermore, whether NAMPT is induced in these cells by
periodontopathogens and IL-1𝛽, which has been shown to
be increased in GCF and gingival tissues at inflamed sites, is
also largely unknown. This study was therefore established
to examine the actions of NAMPT and its regulation by
microbial and inflammatory signals in human PDL cells.
2. Materials and Methods
2.1. Culture and Treatment of Cells. PDL cells were harvested
from periodontally healthy teeth that had to be extracted
for orthodontic reasons. Written informed parental consent
and approval of the Ethics Committee of the University of
Bonn were obtained (#043/11). The cells were cultured in
Dulbecco’s minimal essential medium (DMEM, Invitrogen,
Karlsruhe, Germany) supplemented with 10% fetal bovine
serum (FBS, Invitrogen), 100 units penicillin, and 100 𝜇g/mL
streptomycin (Biochrom, Berlin, Germany) at 37∘C in a
humidified atmosphere of 5%CO
2
. PDL cells from passages 3
to 5 were seeded (50,000 cells/well) on cell culture plates and
grown to 80% confluence. One day prior to the experiment,
the FBS concentration was reduced to 1%. Medium was
changed every other day.
In order to study the actions of NAMPT on PDL cells,
various concentrations of NAMPT (30–300 ng/mL; Biomol,
Hamburg, Germany) were added to cells. To mimic an inf-
lammatory environment, cells were incubated with IL-1𝛽
(0.2–5 ng/mL; Calbiochem, San Diego, CA, USA), as done
in our previous studies [14–16]. In order to simulate an
infectious environment in vitro, cells were stimulated with
the inactivated oral periodontopathogens Porphyromonas
gingivalis ATCC 33277, Tannerella forsythia ATCC 43037,
Treponema denticola ATCC 35405, and Aggregatibacter acti-
nomycetemcomitans Y4 (optical density: 0.025, 0.05, and 0.1).
Bacteria were suspended in PBS (OD
660 nm = 1, equivalent
to 1.2 × 109 bacterial cells/mL) and exposed two times
to ultrasonication (160W for 15min) resulting in a com-
plete killing. In the present study, cells were exposed to
NAMPT, IL-1𝛽, or periodontopathogens for up to 3 d. In
order to unravel the intracellular mechanisms underlying
the effects of NAMPT, PDL cells were preincubated with
specific inhibitors against NF𝜅B (pyrrolidine dithiocarba-
mate, PDTC; 10𝜇M; Calbiochem), JNK (SP600125; 10 𝜇M;
Calbiochem), p38 (SB203580; 10 𝜇M; Calbiochem), MEK1/2
(U0126; 10 𝜇M; Calbiochem), or PI3 K (50 𝜇M; Calbiochem)
signaling pathways 1 h before experiments.
2.2. Microarray Analysis. The regulatory effects of NAMPT
on the gene expression of PDL cells were analyzed by
a genomewide expression profiling using Illumina’s
HumanHT-12 v4 Expression BeadArrays (Illumina, San
Diego, CA, USA). The RNA was reverse transcribed,
amplified, and subsequently biotinylated using the Illumina
TotalPrep-96 RNA Amplification Kit (Life Technologies,
Carlsbad, CA, USA). The resulting cRNA was hybridized to
the arrays according to the manufacturers manual using an
automated liquid handling pipeline and scanned on an IScan
System.The intensity signals were QC checked and exported
using Illumina’s GenomeStudio 2011 v1.1 software suite.
All array data underwent a rigorous quality control,
before applying background correction (subtraction of an
offset, which is estimated from the control probes) and a sub-
sequent variance stabilizing transformation [17], followed by
quantile normalization [18]. All steps were conducted using
the lumi R-package [19]. After calculation of present/absent
calls we only kept probes, which were present in each patient
in each group. In order to consider additional confounding
factors, which might potentially influence gene expression
but are not directly captured by the available patient infor-
mation, we applied the algorithm by Leek and Storey [20],
which estimates a surrogate variable model. In addition,
relative array quality weights were computed via the limma
R-package [21] using the algorithmbyRitchie et al. [22]. Both,
surrogate variables and array weights, can be considered
when fitting a linear model to each gene via limma. In
our case, the limma model contained two additive factors,
namely, a donor and a group factor; that is, essentiallywewere
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fitting 2-way ANOVAmodel. After model fitting, differential
gene expression for all clinically relevant differences can be
extracted as contrasts from the model and corresponding 𝑃
values can be computed (multiple testing correction) [23].
We refer the reader to the limma user guide for an excellent
introduction [24].
2.3. Real-Time PCR. RNA was extracted using an RNA
extraction kit (Qiagen, Hilden, Germany), and a total of
1 𝜇g of RNA was reverse transcribed using iScriptTM Select
cDNA Synthesis Kit (Bio-Rad Laboratories, Munich, Ger-
many) at 42∘C for 90min followed by 85∘C for 5min.
Expression of early growth response 1 (EGR1), MMP-
1, synaptotagmin 7 (SYT7), inositol 1,4,5-trisphosphate 3-
kinase a (ITPKA), CCL2, neurotrimin (NTM), insulin-
like growth factor 2 mRNA-binding protein 3 (IGF2BP3),
neuropilin 1 (NRP1), potassium channel tetramerization
domain-containing protein 12 (KCTD12), heat-shock 27 kD
protein 3 (HSPB3), transmembrane 4 L six family member
20 (TM4SF20), regulator of G protein signaling 4 (RGS4),
NAMPT, COX2, and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was detected by real-time PCR using
the iCycler iQ detection system (Bio-Rad Laboratories),
SYBR Green (Bio-Rad Laboratories), and specific primers
(QuantiTect Primer Assay, Qiagen). One 𝜇L of cDNA was
amplified as a template in a 25𝜇L reactionmixture containing
12.5 𝜇L 2x QuantiFast SYBR Green PCR Master Mix (Qia-
gen), 2.5 𝜇L of primers, and deionized water. The mixture
was heated initially at 95∘C for 5min and then followed by
40 cycles with denaturation at 95∘C for 10 s and combined
annealing/extension at 60∘C for 30 s. GAPDH was used
as an endogenous control. The data were analyzed by the
comparative threshold cycle (CT) method.
2.4. ELISA. The levels of NAMPT, MMP-1, and CCL2 in the
supernatants of PDL cells were analysed by commercially
available enzyme-linked immunoassay (ELISA) kits (Ray-
Biotech, Norcross, GA,USA) according to themanufacturer’s
instructions.The absorbancewasmeasuredwith amicroplate
reader (PowerWave x, BioTek Instruments, Winooski, VT,
USA) at 450 nm. The data were normalized by the cell
number, which was measured with an automatic cell counter
(Moelab, Hilden, Germany).
2.5. Immunocytochemistry. PDL cells were cultured in the
presence and absence of P. gingivalis ATCC 33277 or IL-
1𝛽 on glass coverslips in 24-well plates. After 3 days, cells
were fixed in 4% paraformaldehyde (Sigma-Aldrich,Munich,
Germany) at pH 7.4 and room temperature (RT) for 15min
and then permeabilized in 0.1%TritonX-100 (Sigma-Aldrich)
for 5min. Non specific antigens were blocked by incubation
with serum block (LSAB System; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) for 20min. Subsequently, cells were
incubated at RT for 90min with rabbit polyclonal antibody to
NAMPT (Santa Cruz Biotechnology). Afterwards cells were
labeled with goat anti-rabbit IgG-HRP secondary antibody
(Cell Signalling Technology, Danvers, MA, USA) for 45min.
For staining, cells were exposed to DAB chromogen (Dako,
Hamburg, Germany) for 3min at RT. After each incubation
step, cells were washed twice with PBS (Sigma-Aldrich).
Counterstaining was performed with Mayer’s Haematoxylin
(Merck Eurolab, Dietikon, Switzerland) for 2min. Cover-
slips were mounted in DePex mounting medium (Serva
Electrophoresis, Heidelberg, Germany). Standardized pho-
tomicrographs were taken using an Axioplan 2 imaging
microscope (Carl Zeiss MicroImaging, Jena, Germany).
2.6. Immunofluorescence. PDL cells were fixed with 4%
paraformaldehyde in PBS pH 7.4 for 10min at RT, washed
with PBS, and treated with 0.1% Triton X-100 for 5min at
RT.Then cells were washed again with PBS and blocked with
a blocking buffer (nonfat dry milk; Bio-Rad Laboratories)
for 1 h at RT. After washing, the cells were incubated with
primary rabbit antibody NF𝜅B p65 (1 : 400; Cell Signalling
Technology) for 90min and with secondary antibody CY3
(1 : 2,000; Abcam, Cambridge, MA, USA) for 45min. Cells
were observed under a 20x objective using an Axioplan 2
imaging microscope (Carl Zeiss MicroImaging). The images
were captured with a PVCAM camera and the VisiView
capturing software (Visitron Systems, Puchheim, Germany).
2.7. Statistical Analysis. The IBM SPSS Statistics 20 software
was used for analysis. Mean values and standard errors of
the mean (SEM) were calculated. All experiments were per-
formed in triplicate and repeated at least twice. For statistical
analysis, parametric (𝑡 test and ANOVA followed by the post-
hoc Dunnett’s test) and non parametric tests (Wilcoxon and
Mann-Whitney 𝑈 tests) were applied. Differences between
groups were considered significant at 𝑃 < 0.05. Microarray
data were analyzed in the Bonn-Aachen International Center
for IT, Algorithmic Bioinformatics, University of Bonn,
Germany (see Section 2.2).
3. Results
3.1. Regulation of Gene Expression by NAMPT in PDL Cells.
First, we sought to clarify whether NAMPT regulates the
expression of genes in PDL cells by performing amicroarray-
based approach. As shown in Table 1, NAMPT caused a sig-
nificant upregulation of 9 genes and a significant downregula-
tion of 3 genes in PDL cells from 3 donors at 1 d.TheNAMPT-
upregulated genes were the following: EGR1, MMP-1, SYT7,
ITPKA, CCL2, NTM, IGF2BP3, NRP1, and KCTD12. The 3
NAMPT-downregulated genes comprisedHSPB3, TM4SF20,
and RGS4 (Table 1). In PDL cells from 10 donors, the results
from the microarray analysis were then validated by real-
time PCR,which confirmed 8 out of the 12NAMPT-regulated
genes: NAMPT induced a significant upregulation of the
mRNA expression for EGR1 (2.4-fold), MMP-1 (3.8-fold),
SYT7 (4.6-fold), ITPKA (2.8-fold), CCL2 (2.3-fold), NTM
(2.1-fold), IGF2BP3 (1.9-fold), and NRP1 (1.7-fold). KCTD12
was also upregulated by NAMPT, but the effect did not reach
statistical significance (Table 2 and Figure 1(a)).The effects of
NAMPT on the remaining genes could not be confirmed by
PCR (data not shown).
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Table 1: Regulation of gene expression by NAMPT, as analyzed by
microarray.
Gene LogFC adj. 𝑃 value
EGR1 2.184 0.008
MMP-1 1.545 0.010
SYT7 1.443 0.010
ITPKA 1.292 0.010
CCL2 1.150 0.028
NTM 1.114 0.028
IGF2BP3 1.040 0.020
NRP1 1.024 0.010
KCTD12 1.019 0.048
HSPB3 −1.035 0.030
TM4SF20 −1.164 0.028
RGS4 −1.397 0.025
Effect of NAMPT on gene expression of PDL cells from 3 donors at 1 d. Only
genes with statistically significant (FDR < 5%) logFC ≥ 1 (upregulation
by at least 2-fold) or logFC ≤ −1 (downregulation by at least 50%)
were considered. Abbreviations: EGR1: early growth response 1; MMP-1:
matrix metalloproteinase-1; SYT7: synaptotagmin 7; ITPKA: inositol 1,4,5-
trisphosphate 3-kinase a; CCL2: chemokine, cc motif, ligand 2; NTM:
neurotrimin; IGF2BP3: insulin-like growth factor 2 mRNA-binding protein
3; NRP1: neuropilin 1; KCTD12: potassium channel tetramerization domain-
containing protein 12; HSPB3: heat-shock 27-kD protein 3; TM4SF20:
transmembrane 4 L six family member 20; RGS4: regulator of G protein
signaling 4.
Table 2: Upregulation of gene expression by NAMPT, as analyzed
by real-time PCR.
Gene Fold change(mean) SD SEM 𝑃 value
EGR1 2.422 2.306 0.421 <0.001
MMP-1 3.781 3.116 0.569 <0.001
SYT7 4.575 7.947 1.451 <0.001
ITPKA 2.764 3.182 0.581 0.001
CCL2 2.285 1.346 0.246 <0.001
NTM 2.124 2.460 0.449 <0.001
IGF2BP3 1.897 0.970 0.177 <0.001
NRP1 1.653 1.658 0.303 <0.001
KCTD12 1.713 0.958 0.175 0.095
Effect of NAMPT on gene expression of PDL cells from 10 donors
at 1 d. Abbreviations: EGR1: early growth response 1; MMP-1: matrix
metalloproteinase-1; SYT7: synaptotagmin 7; ITPKA: inositol 1,4,5-
trisphosphate 3-kinase a; CCL2: chemokine, cc motif, ligand 2; NTM:
neurotrimin; IGF2BP3: insulin-like growth factor 2 mRNA-binding protein
3; NRP1: neuropilin 1; KCTD12: potassium channel tetramerization domain-
containing protein 12.
3.2. Effect of NAMPT on MMP-1 and CCL2. Since MMP-1
andCCL2 aremolecules known to be strongly associatedwith
periodontitis, we further studied their regulation byNAMPT.
As observed at 1 d, NAMPT increased significantly theMMP-
1 (1.4-fold) and CCL2 (1.8-fold) expressions at 3 d (Fig-
ure 1(b)). Furthermore, the stimulatory effects of NAMPT
on MMP-1 and CCL2 expressions were dose-dependent at
both time points, as shown in Figures 1(c)–1(f). In addition,
the NAMPT-induced upregulation of the MMP-1 and CCL2
expressions was parallelled by increased MMP-1 and CCL2
protein levels in the supernatants ofNAMPT-stimulated cells,
as compared to those of the control, at 1 d and 3 d (Figures 1(g)
and 1(h)).
3.3. Exploitation of the JNK Pathway by NAMPT. Next, we
studied how the effects of NAMPT on MMP-1 and CCL2 are
mediated intracellularly. As evidenced by immunofluores-
cence microscopy, NAMPT stimulated the nuclear translo-
cation of NF𝜅B and caused a maximal NF𝜅B accumulation
within the nucleus at 60min (Figure 2(a)). However, pre-
incubation of cells with PDTC, a specific inhibitor of NF𝜅B,
had not effect on the NAMPT-stimulated upregulation of
MMP-1 and CCL2 (data not shown). Moreover, the upreg-
ulation of both molecules by NAMPT was also not affected
by inhibitors against the p38, MEK1/2 and PI3K signaling
pathways. However, SP600125, an inhibitor of JNK signaling,
blocked completely the stimulatory effect of NAMPT on the
MMP-1 expression at 1 d (Figure 2(b)). In addition, SP600125
reduced significantly theNAMPT-stimulated upregulation of
CCL2 by 69% at this time point (Figure 2(b)).
3.4. Stimulation of NAMPT Production by P. gingivalis.
We then wondered whether pathogens that are strongly
associated with periodontitis are capable of inducing the
production of NAMPT in PDL cells. Whereas T. denticola,
T. forsythia and A. actinomycetemcomitans had no significant
effect, P. gingivalis increased significantly theNAMPTmRNA
expression at 1 d and 3 d (Figures 3(a) and 3(b)). As shown in
Figures 3(c) and 3(d), the actions of P. gingivalis on NAMPT
mRNA expression were dose-dependent. Interestingly, pre-
incubation with a specific inhibitor against NF𝜅B signaling
blocked completely the P. gingivalis-induced stimulation of
NAMPT at 1 d. Furthermore, inhibitors against JNK and p38
signaling reduced the stimulatory effects of NAMPT by 87%
and 37%, respectively, at this time point.
The stimulation of NAMPT expression by P. gingivalis
was also observed at protein level, as analyzed by ELISA: at
1 d, PDL cells in the presence and absence of P. gingivalis
produced 28.83 ± 0.29 ng NAMPT protein/104 cells and
17.91 ± 0.58 ng NAMPT protein/104 cells, respectively. At
3 d, P. gingivalis-stimulated cells and control cells synthesized
30.97 ± 3.09 ng NAMPT protein/104 cells and 21.65 ±
2.94 ng NAMPT protein/104 cells, respectively. The differ-
ences between both groups at each time point were sig-
nificant. The stimulation of NAMPT protein production by
P. gingivalis was also evidenced by immunocytochemistry
(Figure 4(c)).
Like NAMPT, COX2 was significantly upregulated by P.
gingivalis at 1 d and 3 d (Figures 3(e) and 3(f)). By contrast, all
other periodontopathogens were not capable of stimulating
the COX2 expression at both time points (Figures 3(e)
and 3(f)). The P. gingivalis-induced stimulation of COX2
expression was dose-dependent (Figures 3(g) and 3(h)).
3.5. Stimulation of NAMPT Production by IL-1𝛽. Finally,
we examined whether NAMPT is also induced by IL-1𝛽 in
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Figure 1: Stimulation of gene expression and protein synthesis by NAMPT. Upregulation of genes by NAMPT (100 ng/mL) in PDL cells from
10 donors at 1 d (a). Upregulation ofMMP-1 and CCL2 expression by NAMPT (100 ng/mL) in PDL cells from 10 donors at 3 d (b). Stimulation
of MMP-1 expression by various concentrations of NAMPT in PDL cells from 3 donors at 1 d (c) and 3 d (d). Stimulation of CCL2 expression
by various concentrations of NAMPT in PDL cells from 3 donors at 1 d (e) and 3 d (f). Stimulation of MMP-1 protein synthesis by NAMPT
(100 ng/mL) in PDL cells from 6 donors at 1 d and 3 d (g). Stimulation of CCL2 protein synthesis by NAMPT (100 ng/mL) in PDL cells from
6 donors at 1 d and 3 d (h). All experiments were performed in triplicate and repeated at least twice. Mean ± SEM; ∗significantly (𝑃 < 0.05)
different from NAMPT-untreated cells (control).
PDL cells. Interestingly, IL-1𝛽 upregulated significantly the
NAMPT expression at 1 d and 3 d (Figure 4(a)). Moreover,
the actions of IL-1𝛽 on NAMPT expression were dose-
dependent at 1 d (Figure 1(b)) but not at 3 d (data not shown).
When cells were preincubated with an inhibitor against the
MEK1/2 signaling pathway, the IL-1𝛽-induced stimulation of
NAMPT expression was completely suppressed. Moreover,
inhibitors against JNK, NF𝜅B, and p38 signaling reduced the
stimulatory effect of IL-1𝛽 onNAMPTby 80%, 78%, and 46%,
respectively.
The upregulation of NAMPT at transcriptional level was
paralleled by increased NAMPT protein levels in the super-
natants of IL-1𝛽-stimulated cells: at 1 d, PDL cells in the
presence and absence of IL-1𝛽 synthesized 32.68 ± 3.62 ng
NAMPT protein/104 cells and 20.28 ± 4.36 ng NAMPT
protein/104 cells, respectively. At 3 d, IL-1𝛽-treated cells and
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Figure 2: Intracellular pathways triggered by NAMPT. Stimulation of NF𝜅B nuclear translocation by NAMPT at 60min (a). Inhibition of
the NAMPT-stimulated MMP-1 and CCL2 upregulation by preincubation of PDL cells with SP600125, a selective inhibitor of JNK, at 1 d (b).
Images and data from one representative donor are shown. All experiments were performed in triplicate and repeated at least twice. Mean ±
SEM; ∗significant (𝑃 < 0.05) difference between groups.
Mediators of Inflammation 7
1d
∗
0
N
A
M
PT
 m
RN
A
 ex
pr
es
sio
n
(fo
ld
 o
f c
on
tro
l)
2
1
3
4
5
6
7
8
9
10
Control Pg Td Tf Aa
(a)
3d
∗
0
N
A
M
PT
 m
RN
A
 ex
pr
es
sio
n
(fo
ld
 o
f c
on
tro
l)
2
1
3
4
5
6
7
8
9
10
Control Pg Td Tf Aa
(b)
∗
8
7
9
1d
0
5
1
2
3
4
6
0.025 0.050OD 0.1000.000
N
A
M
PT
 m
RN
A
 ex
pr
es
sio
n
(fo
ld
 o
f c
on
tro
l)
(c)
∗8
7
9
3d
0
5
1
2
3
4
6
0.025 0.050OD 0.1000.000
N
A
M
PT
 m
RN
A
 ex
pr
es
sio
n
(fo
ld
 o
f c
on
tro
l)
(d)
1d
∗
20
30
0
5
1
10
15
Control Pg Td Tf Aa
CO
X2
 m
RN
A
 ex
pr
es
sio
n
(fo
ld
of
 co
nt
ro
l)
25
(e)
3d∗
20
25
30
0
5
1
10
15
Control Pg Td Tf Aa
CO
X2
 m
RN
A
 ex
pr
es
sio
n
(fo
ld
of
 co
nt
ro
l)
(f)
∗
15
20
25
1d
0.025 0.050
0
OD 0.100
1
5
10
0.000
∗
∗
CO
X2
 m
RN
A
 ex
pr
es
sio
n
(fo
ld
of
 co
nt
ro
l)
(g)
∗
15
20
25
3d
∗
0
0.025 0.050OD 0.100
1
5
10
0.000
CO
X2
 m
RN
A
 ex
pr
es
sio
n
(fo
ld
of
 co
nt
ro
l)
(h)
Figure 3: Regulation of NAMPT andCOX2 expressions by periodontopathogens. NAMPT expression in PDL cells from 3 donors in response
to various periodontopathogens (OD: 0.1; P. gingivalis, Pg; T. denticola, Td; T. forsythia, Tf; A. actinomycetemcomitans, Aa) at 1 d (a) and 3 d
(b). Stimulation of NAMPT expression in PDL cells from 3 donors by various concentrations of P. gingivalis (OD: 0.025, 0.050, and 0.100)
at 1 d (c) and 3 d (d). COX2 expression in PDL cells from 3 donors in response to various periodontopathogens (OD: 0.1; P. gingivalis, Pg; T.
denticola, Td; T. forsythia, Tf; A. actinomycetemcomitans, Aa) at 1 d (e) and 3 d (f). Stimulation of COX2 expression in PDL cells from 3 donors
by various concentrations of P. gingivalis (OD: 0.025, 0.050, and 0.100) at 1 d (g) and 3 d (h). All experiments were performed in triplicate and
repeated at least twice. Mean ± SEM; ∗significantly (𝑃 < 0.05) different from P. gingivalis-untreated cells (control).
control cells produced 30.97 ± 3.82 ng NAMPT protein/104
cells and 20.43 ± 0.76 ng NAMPT protein/104 cells, respec-
tively.Thedifferences between groupswere significant at both
time points. The stimulation of NAMPT protein synthesis
by IL-1𝛽 was also observed by immunocytochemistry (Fig-
ure 4(c)).
IL-1𝛽 also induced a significant upregulation of COX2
expression at 1 d and 3 d (Figure 4(d)).
4. Discussion
Our study shows for this first time that NAMPT stimulates
the production ofCCL2 andMMP-1 in humanPDL cells, sug-
gesting that NAMPT may contribute to periodontal inflam-
mation and matrix destruction through the production of
these molecules. Furthermore, NAMPT is induced by the
periodontopathogen P. gingivalis and the proinflammatory
cytokine IL-1𝛽 in PDL cells, which shows that microbial
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Figure 4: Regulation of NAMPT and COX2 expressions by IL-1𝛽. NAMPT expression in PDL cells from 6 donors in response to IL-1𝛽
(1 ng/mL) at 1 d and 3 d (a). Stimulation of NAMPT expression in PDL cells from 3 donors by various concentrations of IL-1𝛽 (0.2, 1.0,
and 5.0 ng/mL) at 1 d (b). NAMPT protein synthesis in PDL cells in the presence and absence of IL-1𝛽 and P. gingivalis at 3 d. Images from
one representative donor are shown (c). COX2 expression in PDL cells from 6 donors in response to IL-1𝛽 (1 ng/mL) at 1 d and 3 d (d). All
experiments were performed in triplicate and repeated at least twice. Mean ± SEM; ∗significantly (𝑃 < 0.05) different from IL-1𝛽-untreated
cells (control).
and inflammatory signals may use this adipokine for their
detrimental effects on the periodontium.
MMP-1 degrades specifically type I collagen and, addi-
tionally, types II, III, V, IX, and X collagen, thereby playing
a critical role for modeling and remodeling of the extracel-
lular matrix [25]. Several studies have revealed that MMP-
1 levels are increased in GCF and human gingiva from
periodontitis patients [26, 27]. Furthermore, MMP-1 levels
could be significantly reduced by periodontal treatment [27].
CCL2 is synthesized by a variety of cell types and regulates
the migration and infiltration of monocytes, memory T
lymphocytes, and natural killer cells. In addition, CCL2 seem
to influence T-cell immunity [28]. Higher levels of CCL2 in
GCF and gingiva from inflamed sites have been reported [20–
31]. Our experiments provide original evidence that NAMPT
induces increased expression and synthesis of MMP-1 and
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CCL2 in human PDL cells, as evidenced by several assays
and in a high number of donors. These findings are in
accordance with previous observations in nonperiodontal
cells and underline the proinflammatory and catabolic role
of NAMPT in the pathophysiology of periodontitis [32–34].
Since increased NAMPT levels are found in obesity, our data
suggest at least one mechanism whereby obesity could confer
an increased risk of periodontitis in obese individuals [5, 9].
Surprisingly, NAMPT also upregulated a number of
genes, most of which have mainly been reported in oncol-
ogy and neurosciences. The transcription factor EGR1 is a
regulator of multiple tumor suppressors but, paradoxically,
can also promote tumor progression [35, 36]. EGR1 is altered
by hypoxia [37], stimulates angiogenesis [35], and regulates
the immune system [38]. Synaptotagmins are transmem-
brane proteins with two Ca2+-binding C(2) domains in their
cytosolic region. Syt7 regulates the exocytosis of lysosomes
and thereby plays a role in bone resorption [39], cell migra-
tion [40], CTL responses [41], and neurodegeneration [42].
ITPKA phosphorylates inositol 1,4,5-trisphosphate, thereby
modulating the calcium (Ca2+) level within the cell and the
levels of a large number of inositol polyphosphates [43].
ITPKA promotes cell motility and the metastatic potential of
tumor cells [43, 44]. Furthermore, ITPKA is critical for the
spatial and temporal regulation of spine actin remodeling,
synaptic plasticity, and learning and memory [45]. Little is
known about neurotrimin, a neural cell adhesion protein. It
has been shown to be an estrogen-regulated determinant of
peripheral sympathetic innervation [46] and to play a role
in axonal fasciculation of specific cerebellar systems and the
formation of excitatory synapses and their stabilization [47].
The IGF2BPs bind to the 5󸀠-untranslated region of IGF-2
mRNA and regulate a number of important aspects of cell
function, such as cell polarization, morphology, migration,
proliferation, differentiation, and invasion [48, 49]. NRP1
plays a critical part in neuronal development, in angiogenesis
and tumor invasion [50, 51]. NRP1 is a coreceptor for
members of the vascular endothelial growth factor family
and the class 3 semaphorins, which are polypeptides with
roles in axonal guidance [52]. Furthermore, NRP1 mediates
interaction of regulatory T cells with dendritic cells and
modulates the immune response [53]. KCTDs act as auxiliary
subunits of GABA(B) receptors and generate desensitizing
receptor responses [54]. Further studies should clarify the
physiological and pathological role of these genes in the
periodontium.
We also sought to examine the intracellular mechanism
whereby the stimulatory effects of NAMPT on MMP-1 and
CCL2 are accomplished. Although NAMPT stimulated the
NF𝜅B nuclear translocation in PDL cells, which concurs with
observations in other cells [32, 55, 56], pre-incubation of cells
with a specific NF𝜅B inhibitor did not abrogate the NAMPT
actions on MMP-1 and CCL2 in our cells. However, the
NF𝜅B signaling pathway could be involved in the NAMPT-
induced upregulation of some of the other genes which were
identified by microarray and PCR analyses. Interestingly, our
experiments revealed that theNAMPT-induced upregulation
ofMMP-1 and CCL2was JNK dependent, which is supported
by findings from others [32].
Recently, increased NAMPT levels have been found in
GCF, gingival tissues, and serum from periodontally diseased
patients, as compared to periodontally healthy individuals.
This suggests that NAMPT might also be produced locally
in the periodontium and regulated by periodontopathogens
and/or inflammatory mediators [12, 13]. Interestingly, we
found that P. gingivalis, a key pathogen associated with
periodontitis, and the proinflammatory cytokine IL-1𝛽,
which is increased at inflamed periodontal sites, can induce
NAMPT in PDL cells, thereby supporting the assumption
that NAMPT is locally produced in the presence of an infec-
tious and/or inflammatory environment. By upregulation
of MMP-1 and CCL2, NAMPT may mediate and amplify
proinflammatory and proteolytic actions of P. gingivalis and
IL-1𝛽 on the PDL. The finding that NAMPT is induced by P.
gingivalis is in linewith our previous experiments, which have
demonstrated that NAMPT is upregulated by F. nucleatum,
a gram-negative, anaerobic microorganism, which acts as a
bridge bacterium between early and late colonizers during
plaque development [57]. Interestingly, T. forsythia, T. den-
ticola, and A. actinomycetemcomitans did not regulate the
NAMPT expression, at least at the concentration tested, in the
present study. Our observation that NAMPT is increased by
IL-1𝛽 in PDL cells concurs with findings in other cells, which
have also been shown to produce increased NAMPT levels
in response to IL-1𝛽 [58–60]. Our data provide evidence
that PDL cells produce increased levels of NAMPT under
infectious and inflammatory conditions, which suggests that
local production of NAMPT in the inflamed periodontium
could contribute to the increased gingival and serum levels of
NAMPT, as observed in patients with periodontitis. NAMPT
could therefore also represent a pathomechanistic link, how
periodontitis affects systemic diseases, such as diabetes mel-
litus and cardiovascular diseases.
Interestingly, the upregulation of NAMPT by P. gingivalis
could be completely blocked by an inhibitor against NF𝜅B
and reduced by inhibitors against the JNK and p38 signaling
pathways. Recently, other investigators have also shown that
P. gingivalis induces NF𝜅B activation and p38 signaling for
its actions [61, 62]. An inhibitor against MEK1/2 signaling
pathway suppressed completely the IL-1𝛽-induced stimula-
tion of NAMPT expression. JNK, NF𝜅B, and p38 signaling
were also found to be involved in the stimulatory effects of
IL-1𝛽 onNAMPT.That IL-1𝛽 exploits theNF𝜅B andmitogen-
activated protein kinase pathways for its actions is well known
and supported by the present findings [63, 64].
In order to simulate an infectious environment, PDL
cells were incubated with a suspension of various periodon-
topathogens. Since the suspensions were exposed to intensive
ultrasonication, the suspensions contained disrupted cell wall
particles with a high amount of lipopolysaccharide. However,
other bacterial components may also have been present
in the suspension. The concentrations used in this study
were determined by dose-response experiments. However, a
significant upregulation of NAMPT was only observed for
P. gingivalis. P. gingivalis is a gram-negative bacterium and
strongly associated with periodontitis. For its detrimental
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effects, P. gingivalis possesses a number of virulence factors,
such as gingipains and fimbriae. P. gingivalis can invade host
cells and also evade the host defense system [65–67]. As
it has been shown in several cells that COX2, an enzyme
which is responsible for the formation of prostanoids, is
upregulated by P. gingivalis and IL-1𝛽, we also analyzed the
COX2 expression as a positive control in our study [61, 62, 68,
69]. As expected, P. gingivalis and IL-1𝛽 increased the COX2
expression in a dose- and time-dependent manner in PDL
cells.
In summary, the present study demonstrates for the first
time that NAMPT stimulates the production of MMP-1 and
CCL2 in human PDL cells, which suggests that NAMPT
may contribute to periodontal inflammation and matrix
destruction through the production of these molecules.
Therefore, increased NAMPT levels, as found in obesity, may
represent at least one mechanism, whereby obesity could
confer an increased risk of periodontitis in obese individ-
uals. In addition, our study provides original evidence that
NAMPT is induced by the periodontopathogen P. gingivalis
and the proinflammatory cytokine IL-1𝛽 in PDL cells, which
shows that microbial and inflammatory signals may use this
adipokine for their detrimental effects on the periodontium.
These findings suggest that local production of NAMPT in
the inflamed PDL could contribute to the increased gingival
and serum levels of NAMPT, as observed in patients with
periodontitis and therefore represent a pathomechanistic
link whereby periodontitis affects systemic diseases, such as
diabetes mellitus and cardiovascular diseases.
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